COX-2 Active agents in the chemoprevention of colorectal cancer

Recent Results in Cancer Research

Volumn 191, Issue , 2013, Pages 95-103

  Kraus, Sarah ^a   Naumov, Inna ^a   Arber, Nadir ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; CYCLOOXYGENASE 3; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; ROFECOXIB;

ADENOMATOUS POLYP; ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CARDIOVASCULAR DISEASE; CHEMOPROPHYLAXIS; COLON ADENOMA; COLON CARCINOMA; COLORECTAL CANCER; DRUG EFFICACY; DRUG WITHDRAWAL; GASTROINTESTINAL TOXICITY; HUMAN; LOW DRUG DOSE; NEPHROTOXICITY; NONHUMAN; PATIENT SELECTION; PERSONALIZED MEDICINE; PRIORITY JOURNAL;

EID: 84867060067     PISSN: 00800015     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-642-30331-9_5     Document Type: Article

References (33)

1. Agarwal B, Rao CV, Bhendwal S et al (1999) Lovastatin augments sulindac-induced apoptosis in colon cancer cells and potentiates chemopreventive effects of sulindac. Gastroenterology 117(4):838-847
2. Arber N, Eagle CJ, Spicak J et al (2006) PreSAP Trial Investigators. Celecoxib for the prevention of colorectal adenomatous polyps N Engl J Med 55(9):885-895
3. Arber N (2008) Cyclooxygenase-2 inhibitors in colorectal cancer prevention: Point. Cancer Epidemiol Biomarkers Prev 17(8):1852-1857
4. Arber N, Levin B (2008) Chemoprevention of colorectal neoplasia; the potential for personalized medicine. Gastroenterology 134(4):1224-1237
5. Arber N, Spicak J, Rácz I et al (2011) Five-year analysis of the prevention of colorectal sporadic adenomatous polyps trial. Am J Gastroenterol 106(6):1135-1146
6. Baron JA, Sandler RS, Bresalier RS et al (2006) Approve Trial Investigators. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas Gastroenterology 131(6):1674-1682
7. Barry EL, Sansbury LB, Grau MV et al (2009) Cyclooxygenase-2 polymorphisms, aspirin treatment, and risk for colorectal adenoma recurrence - data from a randomized clinical trial. Cancer Epidemiol Biomarkers Prev 18(10):2726-2733
8. Bennett A, Del Tacca M. In: Proceedings prostaglandins in human colonic carcinoma Gut 1975; 16(5):409
9. Bertagnolli MM, Eagle CJ, Zauber AG et al (2006) Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 355(9):873-884
10. Bertagnolli MM (2007) Chemoprevention of colorectal cancer with cyclooxygenase-2 inhibitors: Two steps forward, one step back. Lancet Oncol 8:439-443
11. Bertagnolli MM, Eagle CJ, Zauber AG et al (2009) Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial Cancer Prev Res 2(4):310-321
12. Bond J, Graham N, Padovani A et al (2010) Screening for cognitive impairment. Alzheimer's disease and other dementias: Opinions of European caregivers, payors, physicians and the general public J Nutr Health Aging 14:558-562
13. Bresalier RS, Sandler RS, Quan H et al (2005) Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352(11):1092-1102
14. Chan AT, Ogino S, Fuchs CS (2007) Aspirin and the risk of colorectal cancer in relation to the expression of COX-2 N Engl J Med 356(21):2131-2142
15. Chandrasekharan NV (2002) D. H. COX-3, a cyclooxygenase-1 varient inhibited by acetaminophen and other analgesic/antipyretic drugs: Cloning, structure, and expression. Proc Natl Acad Sci U S A 99(21):13926-13931
16. Elder DJ, Baker JA, Banu NA et al (2002) Human colorectal adenomas demonstrate a sizedependent increase in epithelial cyclooxygenase-2 expression. J Pathol 198(4):428-434
17. Etminan M, Gill S, Samil A (2003) Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: Systematic review and meta-analysis of observational studies.BMJ 327:128
18. Greenhough A, Smartt HJ, Moore AE et al (2009) The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis 30(3):377-386
19. Grover JK, Yadav S, Vats V et al (2003) Cyclo-oxygenase 2 inhibitors: Emerging roles in the gut. Int J Colorectal Dis 18(4):279-291
20. Jaffe BM (1974) Prostaglandins and cancer: An update. Prostaglandins 6(6):453-461
21. Lagaos SW (2006) Time-to-event analyses for long-term treatments - the APPROVe trial. N Engl J Med 355(2):113-117
22. Lin HJ, Lakkides KM, Keku TO et al (2002) Prostaglandin H synthase 2 variant (Val511Ala) in African Americans may reduce the risk for colorectal neoplasia. Cancer Epidemiol Biomarkers Prev 11(11):1305-1315
23. Macarthur M, Sharp L, Hold GL et al (2005) The role of cytokine gene polymorphisms in colorectal cancer and their interaction with aspirin use in the northeast of Scotland. Cancer Epidemiol Biomarkers Prev 14(7):1613-1618
24. Mamdani M, Juurlink DN, Lee DS et al (2004) Cyclo-oxygenase-2 inhibitors versus nonselective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: A population-based cohort study. Lancet 363(9423):1751-1756
25. Meyskens FL Jr, McLaren CE, Pelot D, et al (2008) Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: A randomized placebo-controlled double-blind trial. Cancer Prev Res (Phila) 1(1):32-38
26. Pereira C, Pimentel-Nunes P, Brandão C et al (2010) COX-2 polymorphisms and colorectal cancer risk: A strategy for chemoprevention. Eur J Gastroenterol Hepatol 22(5):607-613
27. Rao CV, Reddy BS (2004) NSAIDs and chemoprevention Curr Cancer Drug Targets 4(1):29-42
28. Reddy BS, Wang CX, Kong AN et al (2006) Prevention of azoxymethane-induced colon cancer by combination of low doses of atorvastatin, aspirin, and celecoxib in F 344 rats. Cancer Res 66(8):4542-4546
29. Sheehan KM, Sheahan K, O'Donoghue DP et al (1999) The relationship between cyclooxygenase-2 expression and colorectal cancer. JAMA 282(13):1254-1257
30. Sinicrope FA (2006) Targeting cyclooxygenase-2 for prevention and therapy of colorectal cancer. Mol Carcinog 45(6):447-454
31. Tuynman JB (2004) P. M. COX-2 inhibition as a tool to treat and prevent colon cancer. Crit Rev Oncol Hematol 52(2):81-101
32. Ulrich CM, Bigler J (2006) Potter JD. Non-steroidal anti-inflammatory drugs for cancer prevention: Promise, perils and pharmacogenetics Nat Rev Cancer 6(2):130-140
33. Zell JA, Pelot D, Chen WP, et al (2009) Risk of cardiovascular events in a randomized placebocontrolled, double-blind trial of difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas Cancer Prev Res (Phila) 2(3):209-212